Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Furosemide and Digoxin for Cutaneous Warts
NCT06821594Phase 1Enrolling by invitation
- Sponsor
- Jinnah Postgraduate Medical Centre
- Start
- Apr 2025
- Primary completion
- Aug 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of furosemide and digoxin in cutaneous warts, sponsored by Jinnah Postgraduate Medical Centre. Primary endpoint: Size of cutaneous wart at 5 weeks. Started Apr 2025; status: enrolling by invitation.
02
Drugs
furosemidedigoxin
03
Conditions
cutaneous warts
Beyond the preview
Go deeper on NCT06821594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06821594.